Weekly Ards Research Analysis
This week’s ARDS literature emphasizes mechanistic discovery, practice-defining guidance, and immunometabolic targets. A high-quality preclinical study implicates acid-sensing ion channels (ASICs) in aspiration-evoked cough with implications for aspiration prevention. A GRADE-based 2025 guideline shifts ventilation practice toward early assisted strategies and cautious adoption of adaptive modes. Preclinical immunology work (IL-35 → NRF2/GPX4) highlights ferroptosis modulation as a translational
Summary
This week’s ARDS literature emphasizes mechanistic discovery, practice-defining guidance, and immunometabolic targets. A high-quality preclinical study implicates acid-sensing ion channels (ASICs) in aspiration-evoked cough with implications for aspiration prevention. A GRADE-based 2025 guideline shifts ventilation practice toward early assisted strategies and cautious adoption of adaptive modes. Preclinical immunology work (IL-35 → NRF2/GPX4) highlights ferroptosis modulation as a translational target for sepsis-induced ARDS.
Selected Articles
1. Evidence for acid-sensing ion channel 3 (ASIC3) involvement in cough resulting from aspiration of gastric fluid.
In guinea-pig models, gastric fluid acidity was necessary to trigger cough; vagal airway afferents express ASIC1–3 mRNA, and pharmacologic ASIC inhibition (diminazene, diclofenac) blocked acid-evoked cough and afferent discharge while TRPV1 blockade did not. The study positions ASIC channels as primary mediators of aspiration-evoked airway defense.
Impact: Provides rigorous mechanistic evidence identifying ASIC channels (not TRPV1) as key effectors of acid-evoked cough after aspiration, reframing potential preventive and therapeutic strategies for aspiration-related lung injury and ARDS.
Clinical Implications: Although preclinical, ASICs are nominated as translational targets to enhance airway protection or mitigate aspiration-related lung injury; development of safe ASIC modulators or diagnostics of ASIC dysfunction in at-risk patients may guide future interventions.
Key Findings
- Gastric fluid acidity is essential to evoke cough; citric acid mimics the effect.
- Vagal afferent neurons mediating cough express ASIC1, ASIC2, and ASIC3 mRNA.
- ASIC inhibitors (diminazene, diclofenac) block acid-evoked cough and afferent discharge; TRPV1 blockade does not.
2. Clinical Guideline for Treating Acute Respiratory Insufficiency with Invasive Ventilation and Extracorporeal Membrane Oxygenation: Updated Evidence- Based Recommendations for Choosing Modes and Setting Parameters of Mechanical Ventilation.
A 2025 GRADE-based guideline updates invasive ventilation recommendations: early assisted strategies permitting spontaneous breathing are now favoured over routine early neuromuscular blockade in moderate-to-severe ARDS when clinically appropriate; selective, case-by-case use of adaptive modes (ASV/INTELLiVENT-ASV, NAVA) is suggested while PAV/PAV+ is not recommended; lung-protective targets and individualized PEEP and oxygenation ranges are reinforced.
Impact: This guideline is practice-informing: it consolidates evidence-based ventilator mode choices and parameter targets likely to change ICU ventilation practices and prioritize trials comparing early assisted versus controlled strategies and adaptive modes.
Clinical Implications: Clinicians should consider early assisted ventilation for appropriate ARDS patients, maintain lung-protective VT and driving pressure targets, individualize PEEP using bedside physiology, and selectively trial adaptive modes with monitoring for intolerance.
Key Findings
- Early neuromuscular blockade is no longer routinely favored in moderate-to-severe ARDS; early assisted strategies are suggested when feasible.
- Adaptive modes (ASV/INTELLiVENT-ASV, NAVA) may be considered case-by-case; PAV/PAV+ is not recommended.
- Lung-protective ventilation emphasized: VT ≈6 mL/kg PBW (4–8 mL/kg), plateau ≤30 cmH2O, driving pressure ≤14 cmH2O; individualized higher PEEP for moderate/severe ARDS.
3. IL-35 alleviates ferroptosis in macrophage by activating the NRF2/GPX4 pathway to improve sepsis-induced ARDS.
Preclinical work (in vitro LPS-stimulated macrophages and murine CLP sepsis model) shows IL-35 shifts macrophage polarization toward M2, activates NRF2/GPX4 signaling, reduces macrophage ferroptosis, and lessens lung injury; NRF2 inhibition reverses these effects. Co-cultures with IL-35–treated macrophages reduced epithelial apoptosis and increased IL-10, indicating an immunometabolic mechanism to ameliorate sepsis-induced ARDS.
Impact: Identifies a targetable immunometabolic axis (IL-35 → NRF2/GPX4 → reduced ferroptosis) linking macrophage phenotype to lung epithelial protection—an actionable pathway for translational ARDS immunotherapy development.
Clinical Implications: Translational development of IL-35–based or NRF2/GPX4-activating interventions could complement supportive care for sepsis-induced ARDS; biomarker-driven patient selection (ferroptosis markers) and safety evaluation are early next steps.
Key Findings
- IL-35 inhibits LPS-induced M1 polarization and promotes M2 phenotype in macrophages.
- IL-35 activates NRF2/GPX4 signaling and attenuates macrophage ferroptosis; NRF2 inhibition reverses effects.
- In CLP sepsis model, recombinant IL-35 reduced lung injury and ferroptosis markers; co-culture reduced epithelial apoptosis and increased IL-10.